-
Product Insights
Rho Kinase – Drugs In Development, 2023
Global Markets Direct’s Rho Kinase provides in depth analysis on Rho Kinase targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Rho Kinase targeted therapeutics development and features...
-
Product Insights
Rho Associated Protein Kinase 2 – Drugs In Development, 2023
Global Markets Direct’s Rho Associated Protein Kinase 2 provides in depth analysis on Rho Associated Protein Kinase 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Rho...
-
Product Insights
Rho Guanine Nucleotide Exchange Factor – Drugs In Development, 2023
Global Markets Direct’s Rho Guanine Nucleotide Exchange Factor provides in depth analysis on Rho Guanine Nucleotide Exchange Factor targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Rho...
-
Product Insights
Rho Associated Protein Kinase 1 – Drugs In Development, 2023
Global Markets Direct’s Rho Associated Protein Kinase 1 provides in depth analysis on Rho Associated Protein Kinase 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Rho...
-
Sector Analysis
NewFuchs Endothelial Corneal Dystrophy (FECD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in FECD therapeutics. - More than 133,000,000 total prevalent cases of FECD are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for FECD. - Currently there are no FDA approved therapies for FECD. The most recent guideline for FECD was developed by the American Academy of Ophthalmology. - The pipeline for FECD mainly consists of enzyme inhibitors Rho kinase 2 inhibitor and mTOR...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TDI-01 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TDI-01 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TDI-01 in Cavernous Hemangioma (Cerebral Cavernous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TDI-01 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TDI-01 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TDI-01 in Graft Versus Host Disease (GVHD) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TDI-01 in Pneumoconiosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TDI-01 in Pneumoconiosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TDI-01 in Pneumoconiosis Drug Details: TDI-01 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CPL-409116 in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CPL-409116 in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CPL-409116 in Pulmonary Arterial Hypertension Drug Details: CPL-409116 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belumosudil Mesylate in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belumosudil Mesylate in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belumosudil Mesylate in Refractory Multiple Myeloma Drug Details: Belumosudil mesylate...